Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today report ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 Commission File Number: 001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification ...

Live video webcast on Wednesday, August 20th at 2:40 PM ETOCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:40 PM ET Presenter: Thomas Equels, Chief Executive Officer, President & Executive Vice ChairmanR ...

Core Insights - AIM ImmunoTech Inc. presented its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, highlighting its potential in immunotherapy [1][2] - Dr. Pawel Kalinski emphasized the importance of public-private partnerships in advancing cancer research and treatment development [2][4] - The conference focused on "Opportunities in Singularity," showcasing collaboration between various institutions and organizations [3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [5] - Ampligen, the company's lead product, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist with broad-spectrum activity in clinical trials [5] Future Initiatives - The CEO of AIM stated the goal of establishing clinical partnerships and licensing agreements in Europe, particularly in Poland, to enhance cancer research [4]

Core Viewpoint - AIM ImmunoTech Inc. has received a warning from NYSE American regarding non-compliance with minimum stockholders' equity requirements, with a deadline to regain compliance by June 11, 2026 [2][3]. Group 1: Compliance Issues - As of March 31, 2025, AIM reported a stockholders' deficit of negative $3.9 million, failing to meet the required equity of $4.0 million due to losses in three of the last four fiscal years [2][3]. - The NYSE American had previously issued a warning on December 17, 2024, and the current notification indicates that the deficiency remains unresolved [3]. - AIM has submitted a plan to regain compliance, which has been accepted by NYSE American, allowing until June 11, 2026, to rectify the situation [3]. Group 2: Trading Status - AIM's common stock resumed trading on NYSE American under the symbol "AIM" on June 17, 2025, and the warning does not affect trading or the company's business operations [4]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod) [5].

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [2] Trading Information - AIM ImmunoTech Inc.'s common stock has resumed trading on the NYSE American under the ticker symbol "AIM" effective June 17, 2025 [1]

OTC Pink: AIMI aimimmuno.com Investor Presentation Q2 2025 Forward Looking Statements Immuno-Oncology Immune Disorders Viral Diseases Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this presentation ...

Core Viewpoint - AIM ImmunoTech Inc. has secured a significant patent for the manufacturing of its drug Ampligen, extending patent protection until 2041, which enhances its control over the drug's synthesis and use in various therapeutic applications [1][2][3]. Patent Protection - The newly granted U.S. patent No. 12312376 covers methods for manufacturing a range of therapeutic double-stranded RNA products, including Ampligen, thereby strengthening AIM's intellectual property portfolio [1][2]. - AIM's overall patent portfolio includes protections for Ampligen in treating various conditions, with specific patents expiring between 2039 and 2042 [4]. Development and FDA Approval - The patent extension provides AIM with additional time to develop its drug program and pursue FDA approval for Ampligen across multiple indications, including cancers and viral diseases [3][5]. - AIM's intellectual property also includes multiple Orphan Drug Designations from the FDA and EMA, granting market exclusivity for seven to ten years post-approval for various conditions [5]. Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen being its lead investigational drug, demonstrating broad-spectrum activity in clinical trials [6].

Core Viewpoint - AIM ImmunoTech Inc. has announced the withdrawal of its delisting determination by NYSE Regulation, allowing its common stock to resume trading on the NYSE American starting June 17, 2025 [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials [2]

Group 1 - AIM ImmunoTech Inc. announced a reverse stock split at a ratio of 1-for-100, effective June 12, 2025 [1] - The primary goal of the reverse stock split is to increase the per-share market price to regain compliance with NYSE American's Listing Qualifications [2] - Stockholders approved the reverse stock split at a Special Meeting on April 30, 2025, and will receive cash for any fractional shares post-split [3] Group 2 - AIM ImmunoTech Inc. focuses on the research and development of therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), an investigational drug with broad-spectrum activity in clinical trials [4]